Second phase 3 study of CaPre in patients with severe hypertriglyceridemia

Trial Profile

Second phase 3 study of CaPre in patients with severe hypertriglyceridemia

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Omega-3 phospholipid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 06 Jun 2017 According to an Acasti Pharma media release, the company plans to initiate this study in the second half of 2017.
    • 05 Apr 2017 New trial record
    • 30 Mar 2017 Data from this and another phase III trial (CT profile 700272010) will support the New Drug Application (NDA) for CaPre for the treatment of hypertriglyceridemia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top